Fulgent Genetics (FLGT) Fundamental Analysis: Revenue, Earnings & Valuation

1.02 / 10

Underperform

Fundamental rating is Underperform with a 1.0/10 score. Positive points include strong interest coverage (35.1) and solid fixed‑asset turnover (2.96). However, asset‑to‑market and cash‑to‑market ratios are poor, ROE is negative, and net‑asset growth is declining, indicating weak financial health.

Analysis Checks(4/10)

Net assets per share (growth rate compared to beginning of year %)

Value-2.63

Score2/3

Weight4.86%

1M Return-0.89%

Annualized return on equity (%)

Value-5.39

Score1/3

Weight9.23%

1M Return-2.06%

Quick ratio

Value2.28

Score0/3

Weight16.23%

1M Return-3.43%

Fixed assets turnover ratio

Value2.96

Score3/3

Weight-11.42%

1M Return2.16%

Long-term debt to working capital ratio (%)

Value0.05

Score1/3

Weight17.18%

1M Return-3.85%

Interest coverage ratio (EBIT / Interest expense) (%)

Value35.11

Score2/3

Weight13.81%

1M Return-3.03%

Asset-MV

Value-0.49

Score0/3

Weight23.85%

1M Return-5.93%

ROE (%)

Value-5.39

Score1/3

Weight9.23%

1M Return-2.06%

Current assets / Total assets (%)

Value45.36

Score3/3

Weight-7.83%

1M Return1.48%

Cash-MV

Value0.02

Score0/3

Weight24.86%

1M Return-8.60%

Is FLGT undervalued or overvalued?

FLGT scores 1.02/10 on fundamentals and holds a Premium valuation at present. Backed by its -5.41% ROE, -19.10% net margin, -7.84 P/E ratio, 0.43 P/B ratio, and -39.72% earnings growth, these metrics solidify its Underperform investment rating.